type 2 diabetes

type 2 diabetes
IntDiabetesFed · Public domain · source
Name	Type 2 diabetes
Field	Endocrinology
Symptoms	Hyperglycemia, polyuria, polydipsia, fatigue
Complications	Cardiovascular disease, nephropathy, neuropathy, retinopathy
Onset	Adult
Causes	Insulin resistance, beta-cell dysfunction
Risks	Obesity, family history, sedentary lifestyle
Diagnosis	Fasting plasma glucose, HbA1c, oral glucose tolerance test
Treatment	Lifestyle modification, oral hypoglycemics, insulin

type 2 diabetes

Type 2 diabetes is a chronic metabolic disorder characterized by hyperglycemia due to insulin resistance and progressive pancreatic beta-cell dysfunction. It is a major cause of morbidity and mortality worldwide, linked to cardiovascular disease and multimorbidity across diverse populations. Research and policy responses involve collaborations among institutions such as the World Health Organization, Centers for Disease Control and Prevention, National Institutes of Health, American Diabetes Association, and many national ministries of health.

Epidemiology and Risk Factors

Global prevalence of type 2 diabetes has risen sharply since the late 20th century, with major contributions from demographic shifts and urbanization in regions like China, India, United States, Brazil, and South Africa. Epidemiologic studies from institutions such as the Framingham Heart Study, Nurses' Health Study, UK Biobank, and Global Burden of Disease Study document increasing incidence among middle-aged and older adults. Key population-level risk factors include obesity trends analyzed by the World Obesity Federation and sedentary patterns studied by the World Health Organization and European Society of Cardiology. Individual risk factors include family history (studied in cohorts like the Pima Indians), polycystic ovary syndrome tracked in clinics associated with the American College of Obstetricians and Gynecologists, and certain ethnicities such as Hispanic Americans, African Americans, and South Asians. Socioeconomic determinants identified by agencies including the Organisation for Economic Co-operation and Development and United Nations influence prevalence via food systems, urban design, and health access.

Pathophysiology

Pathophysiology integrates insulin resistance in peripheral tissues (skeletal muscle, adipose, liver) with progressive pancreatic beta-cell failure described in mechanistic studies at centers like the Joslin Diabetes Center and the Eli Lilly and Company research programs. Molecular mechanisms implicate ectopic lipid accumulation, inflammatory pathways involving cytokines studied at the Max Planck Society and mitochondrial dysfunction reported by researchers at the Salk Institute. Genetic susceptibility loci identified through consortia including the Wellcome Trust Case Control Consortium and the International Diabetes Federation highlight variants near genes such as TCF7L2 uncovered in genome-wide association studies coordinated by the National Human Genome Research Institute. Environmental contributors include obesogenic diets influenced by multinational food corporations like Nestlé and PepsiCo, and microbiome alterations explored at institutions such as the Broad Institute and the European Molecular Biology Laboratory.

Clinical Presentation and Diagnosis

Clinical presentation ranges from asymptomatic hyperglycemia detected in screening programs by organizations like the U.S. Preventive Services Task Force to symptomatic cases with polyuria, polydipsia, and fatigue encountered in primary care settings at systems like the Mayo Clinic and Kaiser Permanente. Diagnostic criteria derive from guidelines by the American Diabetes Association, World Health Organization, International Diabetes Federation, and national bodies such as the National Health Service and the Canadian Diabetes Association. Common diagnostic tests include fasting plasma glucose, oral glucose tolerance test, and glycated hemoglobin (HbA1c) assays standardized through programs like the National Glycohemoglobin Standardization Program and laboratories affiliated with the College of American Pathologists.

Management and Treatment

Management combines lifestyle interventions endorsed by the U.S. Department of Health and Human Services, pharmacotherapy developed by companies such as Novo Nordisk, Sanofi, Pfizer, and AstraZeneca, and procedural options performed in specialist centers including bariatric surgery units at the Cleveland Clinic and Johns Hopkins Hospital. First-line therapy emphasizes diet, physical activity, and weight management supported by programs from the American Heart Association and community initiatives modeled on the Diabetes Prevention Program conducted by the National Institutes of Health. Pharmacologic options include metformin recommended by the American Diabetes Association, sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) with cardiovascular outcome data from trials sponsored by pharmaceutical companies and analyzed in journals like The Lancet and the New England Journal of Medicine, GLP-1 receptor agonists developed by firms such as Eli Lilly and Novo Nordisk, sulfonylureas, DPP-4 inhibitors, and insulin regimens managed according to protocols from institutions including the Endocrine Society.

Complications and Prognosis

Macrovascular complications include coronary artery disease, stroke, and peripheral artery disease, outcomes tracked in cohorts such as the INTERHEART study and registries maintained by the American College of Cardiology and European Stroke Organisation. Microvascular complications include diabetic nephropathy leading to end-stage renal disease treated in dialysis centers like those associated with the United States Renal Data System, diabetic retinopathy managed in ophthalmology departments at institutions like the Bascom Palmer Eye Institute, and neuropathy causing foot ulcers addressed by multidisciplinary teams at the International Working Group on the Diabetic Foot. Prognosis is influenced by glycemic control targets recommended by the American Diabetes Association and individualized risk stratification tools developed by research networks including the Framingham Heart Study investigators.

Prevention and Public Health Measures

Prevention strategies emphasize population and high-risk approaches promoted by the World Health Organization, United Nations Children's Fund, and national health agencies such as the Centers for Disease Control and Prevention. Effective programs include lifestyle modification trials like the Diabetes Prevention Program and policy measures on food environments enacted in jurisdictions such as Mexico and Finland. Public health measures involve multisectoral action engaging the Food and Agriculture Organization, urban planners in cities like Copenhagen and Singapore, schools following curricula from the United Nations Educational, Scientific and Cultural Organization, and workplace wellness initiatives implemented by corporations such as Google and IBM to reduce sedentary behavior and improve nutritional choices.

Category:Endocrinology